ReviewExpert review of hematology2014
The serum tryptase test: an emerging robust biomarker in clinical hematology.
Review in Expert review of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 80 citations in OpenAlex.
- Understanding Tryptase Physiology, Clinical Significance, and Diagnostic Applications: Where Do We Stand?Biomolecules · 2026Review
- Biosensors for oral cancer detection: a scoping review.Diagnostic pathology · 2026Article
- Diagnostic Performance of Biomarkers for Perioperative Hypersensitivity Reactions in Adults: A Systematic Review and Meta-Analysis on Tryptase and Histamine Dosing.Diagnostics (Basel, Switzerland) · 2026Review
- The evaluation, management, and future of indolent systemic mastocytosis.Annals of hematology · 2025Review
- Hereditary alpha tryptasemia and clinical implications.World journal of clinical cases · 2025Review
- Severe Anemia With Intraosseous-Intramuscular Hemorrhage in a Patient With Kit-C-Negative Systemic Mastocytosis.Cureus · 2025Article
- BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer.Frontiers in immunology · 2025Article
- Article
- Tryptase: The Silent Witness of Past and Ongoing Systemic Events.Medicina (Kaunas, Lithuania) · 2024Review
- The Clinical Features of Hereditary Alpha-Tryptasemia—Implications for Interdisciplinary Practice.Deutsches Arzteblatt international · 2024Review
- The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT.The journal of allergy and clinical immunology. In practice · 2023Review
- Small bowel obstruction: a rare presentation of systemic mastocytosis.BMJ case reports · 2023Article
- Article
- Estimating the within-subject (CVImmunity, inflammation and disease · 2022Review
- Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: Results of a pilot study.Frontiers in immunology · 2022Article
- Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.HemaSphere · 2021Review
- A Double Histochemical/Immunohistochemical Staining for the Identification of Canine Mast Cells in Light Microscopy.Veterinary sciences · 2021Article
- Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of Anaphylaxis.Current allergy and asthma reports · 2021Review
- Article
- Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.HemaSphere · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 4 countries.
Funding
Abstract
During the past few years, a number of molecular markers have been developed in clinical hematology, most of them related to specific gene defects. However, there is also an unmet need to develop novel serologic parameters to improve diagnostics and prognostication in daily practice. Among these, the serum tryptase appears to be a most reliable biomarker of myeloid neoplasms. Elevated tryptase levels are found in subgroups of patients with mastocytosis, myelodysplastic syndrome, myeloproliferative neoplasm, acute myeloid leukemia, chronic myeloid leukemia and chronic eosinophilic leukemia. In these patients, the tryptase level is of diagnostic and/or prognostic significance. In mastocytosis, an elevated tryptase level is a minor criterion of systemic disease and in BCR-ABL1(+) chronic myeloid leukemia, elevated tryptase at diagnosis correlates with treatment responses and overall survival. In patients with elevated tryptase, the enzyme also serves as follow-up parameter and can be employed to measure treatment-responses. In the current article, we review and update the perspectives of tryptase and provide recommendations for use of this conventional biomarker in daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.